PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 15/00, C07K 14/47, A01K 67/027, C12N 5/10

A1

(11) International Publication Number: **WO 98/58060**

(43) International Publication Date: 23 December 1998 (23.12.98)

(21) International Application Number: PCT/EP98/03686

(22) International Filing Date: 9 June 1998 (09.06.98)

(30) Priority Data:
9712849.0 18 June 1997 (18.06.97) GB

(71) Applicants *(for all designated States except US)*: SMITHKLINE BEECHAM PHARMA GMBH [DE/DE]; Leopoldstrasse 175, D–80804 Munich (DE). SMITHKLINE BEECHAM AUSTRALIA PTY. LTD. [AU/AU]; 300 Frankston Road, Dandenong, VIC 3175 (AU). SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LICHTENTHALER, Stefan [DE/DE]; University of Heidelberg, Im Neuenheimer Feld 282, D–69120 Heidelberg (DE). BEYREUTHER, Konrad [DE/DE]; University of Heidelberg, Im Neuenheimer Feld 282, D–69120 Heidelberg (DE). MASTERS, Colin, Louis [AU/AU]; The University of Melbourne, Parkville, VIC 3052 (AU). BROWN, Frank [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). ALLSOP, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: VALENTINE, Jill; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: HUMAN APP OR A4CT SEQUENCES ENCODING THE MUTATION 145F

(57) Abstract

Constructs comprising a human APP or A4CT DNA sequence encoding mutations which lead to a higher ratio of $\beta A4_{1-42}/\beta A4_{1-40}$ than wild type and their use in the production of transgenic animals developing amyloid plaques as a model of Alzheimer's disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HUMAN APP OR A4CT SEQUENCES ENCODING THE MUTATION 145F

COMPOUNDS

This invention relates to modified amyloid precursor proteins and their use in the production of transgenic animals.

The main protein component of the amyloid plaques found in the brain of Alzheimer's disease (AD) patients is βA4, a 4 kDa peptide consisting of mainly forty and forty-two residues ($\beta A4_{1-40}$, $\beta A4_{1-42}$) being derived from the amyloid precursor protein (APP). APP can exist in multiple forms generated by alternative mRNA splicing. The first form of APP identified by Kang, J., et al., (ref 37) from a foetal brain cDNA library contained 695 amino acids (so-called APP695). This includes a 17 residue signal peptide sequence for transport of the protein into the endoplasmic reticulum. Subsequently, a number of slightly longer cDNA clones were isolated by other workers. The 751 amino acid APP sequence (APP751) described by Ponte, P., et al., (ref 38) contained an additional 57-amino acid insert encoding a Kunitz-type serine proteinase inhibitor (KPI). Kitaguchi, N., et al., (ref 39) identified another precursor of 770 amino acids (APP770) with both the KPI sequence and an additional 19 amino acid insert. These isoforms of APP arise as a result of alternative splicing of exons 7 and 8 during transcription of the APP gene. Additional isoforms generated by alternative splicing of exon 15 have also been detected (ref 40).

APP can be cleaved at the N-terminus of βA4 by an enzyme called β-secretase to generate soluble APP and the C-terminal fragment A4CT (C99). This 99 residue long membrane protein A4CT (ref. 1) which is the direct precursor for βA4 contains the entire βA4 domain, the membrane domain and the cytoplasmic tail of APP. Alternative processing of APP in a post-Golgi-compartment by a protease termed α-secretase leads to the cleavage of APP within the βA4 domain yielding secretory APP and the transmembrane fragment p3CT which is the direct precursor for p3.

Human APP herein refers to all isoforms including the 695 form.

Both C-terminal fragments of APP, A4CT and p3CT, are cleaved within the membrane domain by a γ-cleavage activity, thereby releasing βA4 and p3 into the medium (refs. 2, 3). In cells expressing wild type APP the site of γ-cleavage is mainly the peptide bond Val(40)-Ile(41)of A4CT and to a minor extent the bond Ala(42)-Thr(43). In cells expressing APP with the Familial AD linked mutations at Val 717 (based on APP_{770}, Val 46 of A4CT) an increased γ-cleavage occurs behind Val(42), thus producing larger amounts of $\beta A4_{1-42}$ (ref. 4).

Transgenic mice expressing A4CT have been produced using the human APP promoter (ref. 5), the human thy-1 promoter (ref. 6) and the JC viral early region promoter (ref. 7). Transgenic mice have also been produced expressing amino acids 591-

695 of APP695 (C-terminal 105 amino acids of APP) under control of the human neurofilament NF-L transcriptional regulatory sequences (ref . 41). Numerous promoters have been used inconjunction with the full length APP cDNA (refs. 12, 13, 41, 42, 43, 46). Generation of transgenic mammals bearing APP derived DNA sequences are also described in WO93/14200 (TSI Corporation), WO91/19810 (California Biotechnology Inc), WO93/02189 (University of Calfornia), WO89/00689, WO92/06187 (The Upjohn Company), EP0451700 (Miles Inc.), WO92/13069 (Imperial College of Science Technology and Medicine) and WO89/06689 (McClean Hospital Corporation). In some instances, transgenic mice bearing human mutant APP have been crossed with presenilin-1 transgenics to produce 'double mutant' mice (refs. 44, 45).

Results obtained depend upon the source of the promoter and the protein coding sequence used. However in all cases described to date the nature of the APP-immunoreactive deposits did not resemble the clinical situation and, with the exception of the model described in references 13, 42, 44 and 45 such transgenic animals have not been found to be faithful model systems for Alzheimer's disease.

WO98/03643 (published 29 January 1998) and refs. 36 and 47 disclose constructs comprising mutant human APP or A4CT DNA sequences.

The $\beta A4_{1-42}$ peptide is the major subunit of amorphous and neuritic plaques in Alzheimer's disease.

Applicants have found that recombinant cells expressing A4CT carrying certain mutations in the A4CT amino acid sequence lead to a higher ratio of $\beta A4_{1-42}/\beta A4_{1-40}$ than wild type and such mutant proteins and coding DNA are therefore useful in the production of transgenic animals developing amyloid plaques as a model of Alzhemer's disease. It will be understood that references herein to A4CT, $\beta A4_{1-42}$ and $\beta A4_{1-40}$ include all N-terminal variants produced by alternative cleavage during processing.

According to the present invention there is provided a non-human transgenic mammal whose cells contain a construct comprising a human APP or A4CT DNA sequence encoding the mutation I45F (numbering relative to A4CT).

In a preferred aspect the DNA sequence is operably linked to a promoter sequence.

In a further aspect the construct further encodes an insertion in the transmembrane domain (residues 43 to 52) of a sequence of 1 to 10 amino acid residues; (numbering relative to A4CT) operably linked to a promoter sequence.

The insertion is preferably located between residues 42 and 53, more preferably between 46 and 53. In a preferred embodiment the insertion is located between T48 and L49. The residues for insertion are preferably selected from F, I, G, Y, L, A, P, W, M,

S, T, N and Q. The insertion is preferably 2 to 6 residues long. In a preferred embodiment the insertion is LV.

In a further preferred aspect the construct additionally encodes a mutation selected from:

V46F, V46I, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N or V46Q. In a preferred embodiment the additional mutation is V46F.

In a preferred embodiment the construct comprises an A4CT DNA sequence and further encodes the APP signal sequence (APP residues 1 to 17) immediately upstream of the A4CT DNA sequence. Hydrophobic residue inserts such as LeuGlu or Met are necessary for processing of A4CT to βA4 and should preferably be included between the signal peptide and A4CT coding regions and will remain attached to the processed A4CT.

In a further preferred embodiment the APP is full length APP695.

The invention also relates to mammalian cells expressing the construct and to the DNA construct itself and vectors containing it.

Generation of transgenic mammals of the invention may be carried out conventionally, for example as described in WO93/14200, WO91/19810, WO93/02189, WO89/00689, WO92/06187, EP0451700, WO92/13069 and WO89/06689.

The APP or A4CT coding DNA is obtained by probing a human cDNA library. Mutations may be introduced by site-directed mutagenesis or during construction of the coding DNA from appropriate fragments.

Suitable promoters for use in the present invention include: Human APP (ref. 5); rat neuron specific enolase (neurons) (ref. 18); human ß actin (ref. 19); human PDGFβ (ref. 20); mouse Thy 1 (ref. 21); mouse Prion protein promoter (PrP) (ref. 14); Syrian hamster Prion protein promoter (ref. 35); rat synapsin 1 (brain) (ref. 22); human FMR1 (brain) (ref. 23); human neurofilament low (ref. 24), middle (brain) (ref. 25); NEX-1 (brain) (ref. 26); mouseAPLP2 (brain) (ref. 27); rat alpha tubulin (ref. 28); mouse transferrin (ref. 29); mouse HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase, oligodendrocytes) (ref. 30) and mouse myelin basic protein (ref. 31).

A tetracycline-inducible system may also be used, which has the advantage of regulating the gene expression (induction/repression) (refs. 33, 32). This system uses two constructs: a minimal promoter (PhCMV*-1) fused to seven tetracyclic operator sequences and the cDNA in question; and a trangene containing the tetracycline-controlled tran-activator protein (tTA) coding sequence under the control of a promoter, for example taken from the above list. Each construct is used to generate a transgenic mouse. Crossing the two homozygous mice generates a double transgenic line which expresses the tTA according to the chosen promoter. This tTA induces expression of the

cDNA by activating the PhCMV*-1, but only in the absence of tetracycline. In the presence of tetracycline there is only basal expression.

A preferred promoter is the mouse Prion protein promoter (ref. 14) or hamster Prion protein promoter (ref. 35).

The construct is prepared by conventional recombinant DNA techniques (ref. 10).

The transgenic mammal is produced by conventional techniques (refs. 8, 15, 16, 17).

In one aspect, the transgenic mammal is produced by introduction of the construct into an embryo, insertion of the embryo into a surrogate mother and allowing the embryo to develop to term.

The construct is prepared for transfer to the host animal by cleavage of vector containing the construct and purification of the DNA (ref. 8)

The transfer is carried out conventionally preferably using microinjection as described in detail in reference 8.

In an alternative aspect the transgenic mammal is produced by introduction of the construct into embryonic stem cells by conventional methods such as calcium phosphate/DNA precipitation, direct injection or electroporation (ref. 9) followed by injection of the transformed cells into blastocytes and insertion of the resulting embryo into a surrogate mother as described above.

Transgenic animals are identified by DNA analyis using Southern blot and PCR to detect founder animals.

The transgenic mammal is preferably a rodent such as rat or mouse, more preferably a mouse.

Mammalian cells expressing the construct may be prepared by conventional methods.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the human genes. The culture conditions, such as temperature, pH and the like will be apparent to the ordinarily skilled artisan.

Various mammalian cell culture systems can be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the SH-SY5Y, CHO and HeLa cell lines.

The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as hygromycin or neomycin resistance for eukaryotic cell culture.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Examples of such promoters include the CMV promoter, pCEP4 (Invitrogen) and other promoters known to control expression of genes in eukaryotic cells or their viruses and replicable and viable in the host.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, lipofectin-mediated transfection, or electroporation. (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

The transgenic mammal or cells of the invention may be used to screen for drugs which inhibit deposit of βA4 by administering test drug to the mammal or cell culture medium and observing changes in APP expression and processing, histopathology and/or behavioural changes. The invention extends to such method of screening.

Suitable techniques for making such observations are described in WO93/14200.

Examples

SPA4CT I45F (SEQ ID NOs: 1 and 2)

SPA4CT V46F (FAD mutation).

The above constructs with sequences given in Table 2 were prepared by site directed mutagenesis of wtSPA4CT (ref.1):

wtSPA4CT consists of the 17 amino acid long signal peptide of APP followed by two additional amino acids of APP 695 (Leu and Glu) and then continuing with the βA4 sequence and the whole C-terminal domain and the mutagenesis was carried out in vector

pSP65/SPA4CT (ref. 11) for V46F mutation and pBS/SPA4CT rev for I45F mutation. pBS/SPA4CT rev was obtained by cloning the KpnI/Nhe fragment of pCEP/SPA4CT (ref. 2) in the pBS/SPC99 vector (ref. 34) that was digested with KpnI/XbaI.

The constructs were inserted into pCEP vector (ref. 2) and were stably transfected into COS7 cells.

APP695 I45F (SEQ ID NOs: 3 and 4)

The above construct with sequences given in Table 2 was prepared by site directed mutagenesis of full length wild type APP695 followed by insertion into the SalI site of cosmid cosSHa.Tet (ref. 35), such that the tetracycline resistance gene in the cosmid was replaced by the I45F mutant form of APP695 downstream of the hamster Prion promoter.

Biological activity

Measurement of βA4 in the conditioned medium

Stably transfected COS7 cells were metabolically labeled over night in methionine free MEM-medium containing 10% FCS and 133 µCi/ml ^{35}S-methionine. βA4 and A4CT were immunoprecipated, separated on a 10% Tris-Tricine gel and quantified by phosphorimaging. The following antibodies were used:

G2-10 (monoclonal) against synthetic peptide βA4 33-40 for the immunoprecipitation of $\beta A4_{n-40}$,

G2-11 (monoclonal) against synthetic peptide βA4 35-42 for the immunoprecipitation of $\beta A4_{n-42}$,

692 (polyclonal rabbit serum) against synthetic peptide βA4 1-40 for the immunoprecipitation of βA4.

n-40 and n-42 stand for peptides with a defined C-terminus (ie residue 40 or 42 respectively of βA4) but allowing for possible N-terminal homogeneity. The full length βA4 forms produced by the particular constructs described herein contain Leu, Glu at positions -2, -1.

Detection of A4CT in the cell lysate

The stably transfected COS7 cells were metabolically labeled for 10 min in methionine free MEM-medium containing 133 µCi/ml ^{35}S-methionine. In the cell lysate A4CT was immunoprecipitated with polyclonal antibody against A4CT (ref. 2), separated on a 10% Tris-Tricine gel and quantified by phosphorimaging.

Results

Expression of A4CT

All constructs (wt SPA4CT and mutated SPA4CT) were expressed in similar amounts. The signal peptide of SPA4CT was completely removed leading to Leu-Glu-A4CT.

Release of βA4

All A4CT constructs were processed to βA4 and produce similar amounts of βA4.

Generation of $\beta A4_{1-42}$ and $\beta A4_{1-40}$

For all the constructs both βA4 species $\beta A4_{1-42}$ and $\beta A4_{1-40}$ were released. The ratio $\beta A4_{1-42}/\beta A4_{1-40}$ was determined and the results are shown in Table 1.

Table 1

SPA4CT	$bA4_{1-42}/bA4_{1-40}$	increase of $bA4_{1-42}/bA4_{1-40}$ relative to wt SPA4CT by factor	significance p (student's t test)
wildtype	4.7 ± 1.3	1.0	-
V46F	17.1 ± 4.8	3.6	< 0.001
I45F	161.9 ± 5.7	33.9	<0.001

Conclusions

The FAD linked mutation Val(717)Phe (Val(46)Phe of A4CT) is known to lead to a higher ratio of $\beta A4_{1-42}$/ $\beta A4_{1-40}$ for both SPA4CT and APP compared with the wildtype proteins.

The above results demonstrate that SPA4CT expressing cells (COS7) generate the same βA4 species ($\beta A4_{1-40}$ and $\beta A4_{1-42}$) as APP expressing cells. This suggests that the mechanism of βA4 generation is the same in APP and SPA4CT expressing cells.

The mutations near the C-terminus of βA4 are able to influence the γ-cleavage site, whereas the overall amount of generated βA4 as well as the ratio of βA4/p3 remain unchanged.

The mutant I45F has an increased ratio $\beta A4_{1-42}/\beta A4_{1-40}$ relative to wt.

Generation of transgenic mice expressing mutant SPA4CT or APP695

The above described constructs which produce enhanced production of $\beta A4_{1-42}$ relative to $\beta A4_{1-40}$ are useful for the generation of transgenic mice developing amyloid plaques.

Example 1

The mutant SPA4CT construct driven by the mouse Prion protein promoter (ref. 14) was used to transform a mouse by the following procedures:
The construct is prepared and purified.
Female mice are induced to superovulate and embryos are recovered.
DNA is microinjected into the pronucleus of embryos.
Embryos are transferred into pseudopregnant mice (female mice previously paired with vasectomised males).
Embryos are developed and mice are born.
Founder mice are identified by Southern blot and PCR and bred on.

The mice lines were as follows:
Donor mice (embryos for pronucleus injection): DBA2
Acceptor mice: NMRI
Mice for further breeding: C57Bl/6

Example 2

The full length human APP695 gene carrying the I45F mutation driven by the hamster Prion promotor (ref. 35) was used to generate a mouse also by the procedures of Example 1.
The mice lines were as follows;
Donor mice : C57Bl/6 inbred mice
Recipient mice: [C57Bl/6 x CBA]F1
Mice for further breeding: C57Bl/6

A modification was made to the conventional techniques for generating transgenic animals by microinjection. This modification was to utilize a particularly shaped microinjection needle. The needle is made from the standard borosilicate glass but with a larger tip size and a more splintered shape to that generally used. This was to overcome the slightly larger size of the microinjection fragment used to generate the transgenic mice (approx. 40 kilobases over the standard 1-10 kilobases).

Hybrid [C57Bl/6 x CBA] strain may alternatively be used instead of C57Bl/6.

Screening of drugs using transgenic mice

The transgenic mice described above may be used to screen for potential activity of test drugs in the treatment of Alzheimer's disease.

APP expression and processing may be examined using detection of mRNA by Northern blots and detection of polypeptides using polyclonal and monoclonal antibodies that are specific to the terminal regions of the target peptides.

Histopathological observations may be made using immunohistological techniques to permit identification of amyloid plaques and in situ hybridisation using labelled probes to target mRNA.

Observation of behavioural changes may employ conventional tests used to assess learning and memory deficits.

References

1. Dyrks T., Weidemann A., Multhaup G., Salbaum J. M., Lemaire H.-G., Kang J., Müller-Hill B., Masters C. L., Beyreuther K. (1988), EMBO J. 7, 949-957.

2. Dyrks T., Dyrks E., Mönning U., Urmoneit B., Turner J., Beyreuther K. (1993), FEBS Letters 335, 89-93.

3. Haass C., Hung A. Y., Schlossmacher M. G., Teplow D. B., Selkoe D. J. (1993), JBC 268, 3021-3024.

4. Suzuki N.; Cheung T. T.; Cai X. D.; Odaka A.; Otvos L. Jr.; Eckman C.; Golde T. E., Younkin S. G. (1994), Science 264, 1336-1340.

5. Wirak D. O., et al (1991) Science 253, 323-325.

6. Kawabata S. (1991) Nature 354 476-478.

7. Sandhu F.A. (1991) JBC 266 21331-21334.

8. Hogan et al., 'Manipulating the mouse embryo', Cold Spring Harbor Laboratory, Cold Spring Harbor (1994).

9. 'Teratocarcinomas and embryonic stem cells, a practical approach' ed. E. J. Robertson, IRL Press, 1987.

10. Maniatis et al., 'Molecular Cloning, a Laboratory Manual', Cold Spring Harbor Laboratory, Cold Spring Harbor (1989).

11. Dyrks T., Dyrks E., Masters C., Beyreuther K. (1992), FEBS Letters 309 20-24.

12. Greenberg B.D. et al., Neurobiology of Aging (1996) 17(2) 153-171.

13. Games et al., Nature (1995) 373, 523-527.

14. M. Fischer et al., EMBO J. (1996) 15(6) 1255-64.

15. 'Transgenic animal technology', a Laboratory Handbook ed. C.A. Pinkert (Academic Press Inc 1994).

16. 'Transgenesis Techniques' Principles and Protocols ed. D. Murphy and D.A. Carter (Humana Press, Totowa, New Jersey 1993).
17. 'Teratocarcinomas and Embryonic Stem Cells', a Practical Approach ed. E.J. Robertson (IRL Press 1987).
18. Forss-Petter et al., (1990) Neuron 5;197.
19. Ray et al., Genes and Development 5;2265-2273 (1991).
20. Sasahara et al., Cell 64;217-227 (1991).
21. Ingraham et al., Mol. Cell. Biol. 6(8) 2923-31 (1986).
22. Howland et al., Neurobiol. Aging 16(4) 685-99, (1995).
23. Hergersberg et al., Hum. Mol. Genet. 4(3) 359-66 (1995).
24. Thomas et al., J. Virol. 68(11) 7099-107 (1994).
25. Tu et al., J.Cell. Biol. 129(6) 1629-40 (1995).
26. Bartholoma et al., Mech. Dev. 48(3), 217-8 (1994).
27. Kock et al., J. Biol. Chem. 270(43) 25475-80 (1995).
28. Gloster et al., J. Neurosci. 14(12), 7319-30 (1994).
29. Thiesen et al., Mol. Cell. Biol. 13(12) 7666-76 (1993).
30. Duhamel-Clerin et al., Glia 11(1) 35-46 (1994).
31. Readhead et al.,.Cell 48;703-712 (1987).
32. Baron et al., Nucl. Acids Res. 23(17) 3605-6 (1995).
33. Furth et al., PNAS USA 91, 9302-9306 (1994).
34. Tienari et al., EMBO J 15, 5218-5229 (1996).
35. Scott et al., Prot. Sci. 1, 986-997 (1992).
36. Lichtenthaler et al., Neurobiology of Aging 17(4) supp, s130-s131 abstract 524.
37. Kang et al., Nature (1987) 325:733-736.
38. Ponte et al., Nature (1998) 331: 525-527.
39. Kitaguchi et al., Nature (1988) 331:530-532.
40. Sandbrink, et al., J. Biol. Chem. (1994) 269: 1510-1517.
41. Nalbantoglu et al., Nature (1997) 387: 500-505.
42. Hsiao et al., Science (1996) 274, 99-103.
43. Sturchler-Pierrat et al., Proc. Natl. Acad. Sci. USA (1997) 94: 13287-13292.
44. Borchelt et al., Neuron (1997) 19: 939-945.
45. Holcomb et al., Nature Med. (1998) 4: 97-100
46. Duff, Trend Neurosci. (1997) 20: 279-80
47. Lichtenthaler et al., Biochemistry (1997) 36: 15396-15403

Table 2: Sequence listings

SPA4CT I45F

Protein
SEQ ID NO: 1
MLPGLALLLLAAWTARALEDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVFVITLVMLK
KKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN

DNA
SEQ ID NO: 2
ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGATGCAGAATTCCGA
CATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGT
GCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTTTTCGTCATCACCTTGGTGATGCTGAAG
AAGAAACAGTACACATCCATTCATCATGGTGTGGTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCAC
CTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAAC

APP695 I45F

Protein
SEQ ID NO: 3
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQY
CQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVC
ETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTD
YADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVR
EVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNRNNFDTEEYCMAVCGSAIPTTAASTPDAVD
KYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAAN
ERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDP
KKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDA
LMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTE
EISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVFVITLVMLKKKQYTSIHHGVV
EVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN

DNA
SEQ ID NO: 4
ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTACCCACTGATGGT
AATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGACTGAACATGCACATGAATGTCCAG
AATGGGAAGTGGGATTCAGATCCATCAGGGACCAAAACCTGCATTGATACCAAGGAAGGCATCCTGCAGTAT
TGCCAAGAAGTCTACCCTGAACTGCAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAAC
TGGTGCAAGCGGGGCCGCAAGCAGTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGT
GAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGGATGGATGTTTGC
GAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAGAAGAGTACCAACTTGCATGACTAC

GGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAA
AGTGACAATGTGGATTCTGCTGATGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGAC
TATGCAGATGGGAGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAA
GAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAACCCTACGAAGAA
GCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACAGAGTCTGTGGAAGAGGTGGTTCGA
GAGGTGTGCTCTGAACAAGCCGAGACGGGGCCGTGCCGAGCAATGATCTCCCGCTGGTACTTTGATGTGACT
GAAGGGAAGTGTGCCCCATTCTTTTACGGCGGATGTGGCGGCAACCGGAACAACCGGAACAACTTTGACACA
GAAGAGTACTGCATGGCCGTGTGTGGCAGCGCCATTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGAC
AAGTATCTCGAGACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCC
AAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCAAAGAACTTGCCT
AAAGCTGATAAGAAGGCAGTTATCCAGCATTTCCAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCCAAC
GAGAGACAGCAGCTGGTCGAGACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCC
CTGGAGAACTACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAGAAG
TATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTGCGCATGGTGGATCCC
AAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTATGAGCGCATGAATCAGTCT
CTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAA
GAGCAAAACTATTCAGATGACGTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCT
CTCATGCCATCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGAC
GATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTT
GATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAATATCAAGACGGAG
GAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTG
GTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATA
GCGACAGTCTTCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTGGTG
GAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCA
ACCTACAAGTTCTTTGAGCAGATGCAGAACTAG

Claims

1. A construct comprising a human APP or A4CT DNA sequence encoding the mutation I45F (numbering relative to A4CT)
2. A construct according to claim 1 where the DNA sequence is operably linked to a promoter sequence.
3. A construct according to claim 1 wherein the construct further encodes an insertion in the transmembrane domain (residues 43 to 52) of a sequence of 1 to 10 amino acid residues (numbering relative to A4CT).
4. A construct according to claim 3 wherein the insertion is located between T48 and L49.
5. A construct according to claim 3 or 4 wherein the residues for insertion are selected from F, I, G, Y, L, A, P, W, M, S, T, N and Q.
6. A construct according to any of claims 3 to 5 wherein the insertion is 2 to 6 residues long.
7. A construct according to claim 6 wherein the insertion is LV.
8. A construct according to any preceding claim wherein the construct additionally encodes a mutation selected from:

V46F, V46I, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N or V46Q.

9. A construct according to any preceding claim wherein the construct comprises an A4CT DNA sequence and further encodes the APP signal sequence (APP residues 1 to 17) immediately upstream of the A4CT DNA sequence together with hydrophobic residue inserts between the signal peptide and A4CT coding regions.
10. A construct according to any preceding claim comprising a mammalian promoter selected from Human APP; rat neuron specific enolase (neurons); human ß actin; human PDGFβ; mouse Thy 1; mouse Prion protein promoter (PrP); Syrian hamster Prion protein promoter; rat synapsin 1 (brain); human FMR1 (brain); human neurofilament low, middle (brain); NEX-1 (brain); mouseAPLP2 (brain); rat alpha tubulin; mouse transferrin; mouse HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase, oligodendrocytes) and mouse myelin basic protein.
11. A construct according to claim 1 comprising the sequence SPA4CT I45F (SEQ ID NO: 2).
12. A construct according to claim 11 wherein the DNA sequence is operably linked to mouse Prion protein promoter (PrP).
13. A construct according to claim 1 comprising the sequence APP695 I45F (SEQ ID NO: 4)

14. A construct according to claim 13 wherein the DNA sequence is operably linked to Syrian hamster Prion protein promoter.

15. A non-human transgenic mammal whose cells contain a construct according to any preceding claim.

16. A transgenic mammal according to claim 15 which is a rodent.

17 A transgenic mammal according to claim 16 which is mouse strain C57Bl/6.

18. A mammalian host cell expressing the construct of any of claims 1 to14.

19. A vector containing the construct of any of claims 1 to 14.

20. A method of screening for drugs which inhibit deposit of βA4 by administering test drug to the transgenic mammal of claim 15, 16 or 17 or cell culture medium containing the mammalian host cell of claim 18 and observing changes in APP expression and processing, histopathology and/or behavioural changes.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/03686

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N15/00 C07K14/47 A01K67/027 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LICHTENTHALER S ET AL: "MUTATIONS NEAR THE C-TERMINUS OF BETAA4 INFLUENCE THE GAMMA-CLEAVAGE OF A4CT (C99) IN COS7 CELLS" NEUROBIOLOGY OF AGING, vol. 17, no. 4, SUPPL, 19 July 1996, page S130 XP002056699 see the whole document ---	1-8
A,P	LICHTENTHALER S F ET AL: "MUTATIONS IN THE TRANSMEMBRANE DOMAIN OF APP ALTERING GAMMA SECRETASE SPECIFICITY" BIOCHEMISTRY, vol. 36, no. 49, 9 December 1997, pages 15396-15403, XP002056700 see the whole document ---	3,8

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publicationdate of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of theinternational search	Date of mailing of the international search report
30 October 1998	10/11/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Chambonnet, F

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/03686

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 98 03643 A (MASTERS COLIN LOUIS ;SMITHKLINE BEECHAM AUSTRALIA P (AU); BEYREUTH) 29 January 1998 see the whole document	3,8

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

In ational Application No
PCT/EP 98/03686

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9803643 A	29-01-1998	NONE	